Ron Bentsur Insider Profile
11 Followers
Ron Bentsur, Chairman & CEO, Director, Ten Percent Owner at Nuvectis Pharma, holds 3.69M shares in Nuvectis Pharma (Ticker: NVCT), holds 144.74K shares in Beyond Air (Ticker: XAIR), holds 0.00 shares in Stemline Therapeutics (Ticker: STML). Most recently, Ron Bentsur Bought ― shares of Nuvectis Pharma on Jul 01, 2026 for an estimated value of $250.00K.
Ron Bentsur Nuvectis Pharma (NVCT)Chairman & CEO, Director, Ten Percent Owner
Nuvectis Pharma (NVCT)
Chairman & CEO, Director, Ten Percent Owner
Ranked #3,190 out of 108,575 Corporate Insiders
Profitable Transactions
36 out of 61 Profitable Transactions
Average Return
+14.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ron Bentsur holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ron Bentsur
Ron Bentsur's Trading History
Nuvectis Pharma
Jul 01, 2026
Chairman & CEO, Director, Ten Percent Owner
Informative Buy
250.00K
$86.05M
Beyond Air
Mar 21, 2023
Director
Informative Buy
14.90K
$754.07K
Keryx Biopharma
Apr 08, 2015
―
Informative Sell
18.59K
$2.61M
Stemline Therapeutics
Jun 10, 2020
―
Uninformative Sell
―
$0.00
XTL Biopharmaceuticals Sponsored ADR
―
CEO
―
$59.90K
List of latest transactions for each holding click on a transaction to see Ron Bentsur's performance on stock
You May Also Like
Ron Bentsur insider profile FAQ
What is the percentage of profitable transactions made by Ron Bentsur?
The percentage of profitable transactions made by Ron Bentsur is 59%.
What is the average return per transaction made by Ron Bentsur?
The average return per transaction made by Ron Bentsur is 14.50%.
What stocks does Ron Bentsur hold?
Ron Bentsur holds: NVCT, XAIR, KERX, STML, XTLB stocks.
What was Ron Bentsur’s latest transaction?
Ron Bentsur latest transaction was an Informative Buy of $250.00K.
What was Ron Bentsur's most profitable transaction?
Ron Bentsur’s most profitable transaction was an Informative Buy of NVCT stock on November 6, 2025. The return on the trade was 234.30%.
What is Ron Bentsur's role in Nuvectis Pharma?
Ron Bentsur's role in Nuvectis Pharma is Chairman & CEO, Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.